Vimarsana
Biggest News Aggregation in the World

Visual Evoked Potential News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Visual Evoked Potential. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Visual Evoked Potential Today - Breaking & Trending Today

"Conflict and control in cortical responses to inconsistent emotional s" by Graham A. Jamieson, Julia Page et al. - Vimarsana News

"Conflict and control in cortical responses to inconsistent emotional s" by Graham A. Jamieson, Julia Page et al.

Social communication is fraught with ambiguity. Negotiating the social world requires interpreting the affective signals we receive and often selecting between channels of conflicting affective information. The affective face-word Stroop (AFWS) provides an experimental paradigm which may identify cognitive-affective control mechanisms underpinning essential social-affective skills. Initial functional magnetic resonance imaging (fMRI) study of the AFWS identified right amygdala as driving this affective conflict and left rostral anterior cingulate cortex (rACC) as the locus of conflict control....

Source: uow.edu.au
Electroretinography Market Size to Hit USD 62.72 million by 2027 - Vimarsana News

Electroretinography Market Size to Hit USD 62.72 million by 2027

Fixed electroretinography segment is expected to grow the market for electroretinography over the forecast period for product segment.

LumiThera, Inc. Announces Purchase of MacuLogix Assets - Vimarsana News

LumiThera, Inc. Announces Purchase of MacuLogix Assets

SEATTLE, July 26, 2022 /PRNewswire/ -- LumiThera Inc., a commercial stage medical device company offering photobiomodulation (PBM) treatment for

LumiThera, Inc. Announces Purchase of MacuLogix Assets - Vimarsana News

LumiThera, Inc. Announces Purchase of MacuLogix Assets

/PRNewswire/ -- LumiThera Inc., a commercial stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today...

LumiThera Announces US LIGHTSITE III Clinical Trial Meets Primary Efficacy Endpoint in Improving Vision in Dry Age-Related Macular Degeneration Subjects - Vimarsana News

LumiThera Announces US LIGHTSITE III Clinical Trial Meets Primary Efficacy Endpoint in Improving Vision in Dry Age-Related Macular Degeneration Subjects

/PRNewswire/ -- LumiThera Inc., a commercial stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today...